干呕
医学
麻醉
呕吐
术后恶心呕吐
恶心
止吐药
安慰剂
胆囊切除术
全身麻醉
外科
病理
替代医学
作者
Yoshitaka Fujii,Akira Uemura,Hiroyoshi Tanaka
出处
期刊:European Journal of Surgery
[Oxford University Press]
日期:2002-01-01
卷期号:168 (11): 583-586
被引量:29
标识
DOI:10.1080/11024150201680002
摘要
To evaluate the efficacy and safety of ramosetron (a 5-hydroxytryptamine type 3 receptor antagonist) for the prevention of nausea and vomiting after laparoscopic cholecystectomy.Prospective, randomised, double-blind, placebo-controlled study.University and university-affiliated hospitals, Japan.100 patients, 65 women and 35 men, who had laparoscopic cholecystectomy.Patients were given either placebo or ramosetron at 3 different doses (0.15 mg, 0.3 mg, 0.6 mg) intravenously at the completion of operation. The general anaesthetic technique and postoperative analgesia were standard.Vomiting and safety were assessed for 0 to 24 hours and 24 to 48 hours after anaesthesia.The number of patients who had a complete response (no nausea, no retching, no vomiting) during 0 to 24 hours after anaesthesia was 15/25 with placebo, 17/25 with ramosetron 0.15 mg, 23/25 with ramosetron 0.3 mg, and 23/25 with ramosetron 0.6 mg; The corresponding numbers from 24 to 48 hours were 16, 17, 23, and 23. No serious adverse events were observed in any of the groups.Ramosetron 0.3 mg was the minimum effective dose for preventing postoperative nausea and vomiting during 0 to 48 hours after anaesthesia in patients undergoing laparoscopic cholecystectomy.
科研通智能强力驱动
Strongly Powered by AbleSci AI